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ABSTRACT
Background Immune checkpoint inhibitors that target 
the programmed cell death protein 1 (PD-1) receptor 
induce a response in only a subgroup of patients with 
metastatic melanoma. Previous research suggests that 
transforming growth factor beta signaling and a collagen- 
rich peritumoral stroma (tumor fibrosis), may negatively 
interfere with the interaction between T cells and tumor 
cells and thereby contribute to resistance mechanisms by 
immune- exclusion, while increased tumor infiltration of 
M1- like macrophages enhances T cell activity. Hence, the 
current study aimed to assess the relationship between 
blood- based markers of collagen or vimentin turnover 
(reflecting M1 macrophage activity) and clinical outcome in 
patients with metastatic melanoma after PD-1 inhibition.
Methods Patients with metastatic melanoma who 
were treated with anti- PD-1 monotherapy between May 
2016 and March 2019 were included in a prospective 
observational study. N- terminal pro- peptide of type III 
collagen (PRO- C3) cross- linked N- terminal pro- peptides 
of type III collagen (PC3X), matrix metalloprotease (MMP)- 
degraded type III (C3M) and type IV collagen (C4M), 
granzyme B- degraded type IV collagen and citrullinated 
and MMP- degraded vimentin (VICM) were measured with 
immunoassays in serum before (n=107), and 6 weeks 
after the first administration of immunotherapy (n=94). The 
association between biomarker levels and overall survival 
(OS) or progression- free survival (PFS) was assessed.
Results Multivariate Cox regression analysis identified 
high baseline PRO- C3 (Q4) and PC3X (Q4) as independent 
variables of worse PFS (PRO- C3: HR=1.81, 95% CI=1.06 
to 3.10, p=0.030 and PC3X: HR=1.86, 95% CI=1.09 
to 3.18, p=0.023). High baseline PRO- C3 was also 
independently related to worse OS (HR=2.08, 95% 
CI=1.06 to 4.09, p=0.035), whereas a high C3M/PRO- C3 
ratio was related to improved OS (HR=0.42, 95% CI=0.20 
to 0.90, p=0.025). An increase in VICM (p<0.0001; in 56% 
of the patients) was observed after 6 weeks of treatment, 
and an increase in VICM was independently associated 
with improved OS (HR=0.28, 95% CI=0.10 to 0.77, 
p=0.014).
Conclusions Blood- based biomarkers reflecting 
excessive type III collagen turnover were associated with 
worse OS and PFS after PD-1 inhibition in metastatic 
melanoma. Moreover, an increase in VICM levels after 
6 weeks of treatment was associated with improved OS. 
These findings suggest that type III collagen and vimentin 
turnover contribute to resistance/response mechanisms of 
PD-1 inhibitors and hold promise of assessing extracellular 
matrix- derived and stroma- derived components to predict 
immunotherapy response.
BACKGROUND
Over the last decade, immune checkpoint 
inhibitors (ICIs) have improved the overall 
survival (OS) of patients with metastatic 
cancer. Monoclonal antibodies directed to 
the programmed cell death protein 1 (PD-1) 
receptor have emerged as frontline ther-
apies for cancers such as metastatic mela-
noma. However, there is an unmet need for 
biomarkers to guide treatment decisions, as 
the efficacy of ICIs is highly variable across 
individual patients. Although the expression 
of its ligand programmed death- ligand 1 (PD- 
L1) has been positively associated with clinical 
outcome in metastatic melanoma, the predic-
tive performance remains limited, which may 
partly be explained by tumor heterogeneity.1 
Similarly, other biomarkers, such as CD8+ 
T cell infiltration and tumor mutational 
burden, individually or combined, have been 
considered as biomarkers.2 3 Interestingly, 
recent evidence suggests that transforming 
growth factor beta (TGF-β), cancer- associated 
fibroblasts (CAFs) and immune- exclusion in 
tumor tissue are associated with worse clin-
ical outcome after PD- L1 or PD-1 inhibition 
in solid cancer.4–6 Those immune- excluded 
tumors are characterized by a collagen- rich 
peritumoral stroma (tumor fibrosis) that 
blocks the interaction between CD8+ T cells 
and tumor cells.4–6 The main collagens of the 
interstitial matrix (type I and III collagen) and 
the basement membrane (type IV collagen) 
are upregulated in immune- excluded tumors 
that are accompanied by a peritumoral loca-
tion of CD8+ T cells.7 Moreover, components 
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of proteolytic extracellular matrix (ECM) turnover 
appear to affect the response mechanisms to ICIs by regu-
lating steps in the cancer- immunity cycle.8 Melanoma 
is characterized by a highly reactive and fibrotic tumor 
stroma.9 10 Increased stroma activity leads to increased 
matrix metalloproteinase (MMP)- mediated collagen 
degradation resulting in the generation and release of 
small protein fragments containing specific protease- 
generated neo- epitopes into the blood circulation.11 12 
These ECM protein fragments can be used as non- invasive 
biomarkers measured in blood, and may be used to assess 
processes such as MMP- mediated collagen degradation 
and collagen formation and cross- linking by evaluating 
its blood- based signature.12 This has been demonstrated 
by our previous study showing that biomarkers measuring 
N- terminal pro- peptide of type III collagen (PRO- C3) or 
MMP- degraded type IV collagen (C4M) are associated 
with worse clinical outcome after cytotoxic T- lymphocyte- 
associated protein 4 (CTLA-4) ICIs in patients with meta-
static melanoma.13 The two collagen- derived biomarkers 
assess different components of the ECM in the tumor 
microenvironment (TME) by reflecting a dense stromal 
interstitial matrix and fibrotic activity (PRO- C3) and 
degradation of the basement membrane (C4M).14
The current study aimed to investigate the relationship 
of tissue- derived biomarkers and clinical outcome after 
PD-1 inhibition in patients with metastatic melanoma. 
Protein fragments reflecting type III collagen formation 
(PRO- C3) and cross- linking (PC3X), MMP- degraded type 
III (C3M) and IV collagen (C4M), granzyme B- degraded 
type IV collagen (C4G) and citrullinated and MMP- 
degraded vimentin (VICM) were measured in serum 
obtained before and 6 weeks after the first administration 
of PD-1 ICIs. Moreover, the dynamics of collagen turn-
over and VICM during treatment were assessed.
METHODS
Study design and data collection
Patients with metastatic melanoma who were treated with 
anti- PD-1 monotherapy (pembrolizumab or nivolumab) 
at the Erasmus MC Cancer Institute (Rotterdam, The 
Netherlands) were prospectively included in the MULT-
OMAB immune- monitoring trial (Dutch Trial Registry 
number NL6828) between May 2016 and March 2019, 
with a mean follow- up time of 1.8 years (SD: 10 months). 
Pembrolizumab was administered as a 3 weekly infusion 
of 2 mg/kg, and nivolumab as a 2 weekly infusion of 3 mg/
kg. Patients who were treated with a prior line of immu-
notherapy or who received combination ICI therapy were 
excluded. Serum samples drawn at baseline and after 
6 weeks (median 6, IQR 6–9 weeks) of treatment were 
available for the assessment of selected ECM biomarkers. 
All biomarker assays were performed blinded to clinical 
outcome and subject numbers were assigned to patients. 
The biomarker analyses were performed in August 2019. 
Progression- free survival (PFS) was defined as the time 
from the first administration of PD-1 ICI until progressive 
disease (PD; based on Response Evaluation Criteria in 
Solid Tumors version 1.1 (RECIST V.1.1))15 or death, 
whichever occurred first. OS was defined as the time from 
the first administration of PD-1 ICI until death. After 
treatment initiation, radiological evaluation by CT was 
usually performed every 3 months. For the determina-
tion of the best overall response (BOR) by RECIST V.1.1, 
a minimum duration of 90 days for stable disease (SD) 
was required. Confirmation of partial response (PR) or 
complete response (CR) was not required.
Assessment of biomarkers of extracellular matrix turnover in 
serum
Levels of ECM biomarkers were assessed in duplicates in 
serum samples using immunoassays (Nordic Bioscience, 
Herlev, Denmark) as previously described.7 In short, type 
III collagen formation were measured with a competitive 
ELISA targeting the PRO- C3. Moreover, type III collagen 
formation and cross- linking were measured with a sand-
wich ELISA targeting PC3X. C4G was measured with a 
competitive electrochemiluminescence assay. Lastly, 
C3M, C4M and VICM were measured with competitive 
ELISAs.
Statistical analysis
First, patient survival (PFS and OS) was visualized by the 
Kaplan- Meier approach and log- rank tests were used to 
determine differences between the curves after stratifica-
tion of patients into quartile groups based on biomarker 
levels. Kaplan- Meier survival curves were also used to 
analyze survival outcomes in patients with a low type III 
collagen degradation to formation (C3M/PRO- C3) ratio 
(<1) compared with a high C3M/PRO- C3 ratio (>1). 
Moreover, survival outcomes were analyzed in patients 
with an evident increase in biomarkers (>20%) at week 6 
compared with baseline versus the rest of the patients who 
did not have an evident increase. The association with 
survival (PFS and OS) was further analyzed using univar-
iate and multivariate Cox regression analysis. Correction 
for potential confounding factors was performed, variables 
with a p value of ≤0.05 were considered for multivariate 
analyses. Test variables (ECM biomarkers) were included 
as continuous variable and stratified by the 75th percen-
tile cut- off. Second, to study the association of baseline 
ECM biomarker levels with BOR, patients with PD were 
compared with patients with SD/PR/CR and analyzed 
using the Mann- Whitney U test. Lastly, the dynamics of 
ECM biomarkers were studied by determining the differ-
ence over time of individual ECM biomarkers, indicating 
an increase or decrease comparing baseline levels with 
levels during therapy using the Wilcoxon matched- pairs 
rank test. A Pearson’s correlation (two- tailed) was used 
to examine biomarker correlations, as well as the correla-
tions of baseline biomarker levels with lactate dehydro-
genase (LDH). Analyses were performed using MedCalc 
(V.16.8.4), IBM SPSS Statistics V.24.0.0.1 (Chicago, Illi-
nois, USA) and Graphpad Prism V.8.3.0 (Graphpad 
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Software). A p value of p<0.05 was considered to be statis-
tically significant.
RESULTS
Serum from a total of 107 patients with metastatic mela-
noma at baseline and paired serum from 94 patients (88% 
of all patients) that was obtained 6 weeks (median 6, IQR 
6–9 weeks) after PD-1 ICI therapy was available for anal-
ysis. The baseline patient characteristics including demo-
graphic and clinical data are shown in table 1. Patients 
generally received PD-1 ICIs as first- line treatment shortly 
after diagnosis (82% of all patients), and therefore gener-
ally have a good performance status (WHO PS 0 or 1: 92% 
of all patients). All 107 patients were evaluable for the OS 
analysis, with a median OS of 36.2 months. Three patients 
(3%) were not evaluable for determination of BOR, that 
is, because of early clinical progression, resulting in a 
disease control rate (the proportion of patients with a 
BOR of SD, PR or CR) of 63.5%. The serum levels of the 
six different ECM biomarkers were evaluated at baseline: 
PRO- C3, PC3X, C4G, C3M, C4M and VICM. The distribu-
tion of those baseline measurements is shown in online 
supplemental figure 1. For all six ECM biomarkers, there 
was a right- skewed distribution of data.
Baseline levels of PRO-C3 and PC3X are negatively associated 
with survival outcomes when assessed by Kaplan-Meier 
method
First, the relationship between ECM- derived biomarkers 
at baseline and clinical outcome after PD-1 inhibition 
in patients with metastatic melanoma were investigated 
by the Kaplan- Meier method. For PRO- C3 and PC3X, 
statistically significant differences among PFS curves were 
observed across the quartiles of biomarker levels (median 
PFS of PRO- C3 Q1: 28.4 months, Q2: not reached, Q3: 
12.9 months and Q4: 2.6 months, p=0.028 and median 
PFS of PC3X Q1: 26.9 months, Q2: 9.1 months, Q3: 23.3 
months and Q4: 3.2 months, p=0.035; figure 1A,B). Simi-
larly, the association of ECM biomarkers with OS was 
assessed (figure 2), resulting in a corresponding trend 
for PRO- C3 and PC3X (median OS of PRO- C3 Q1: 42.3 
months, Q2: not reached, Q3: 36.2 months and Q4: 13.9 
months, p=0.056 and median OS PC3X Q1: not reached, 
Q2: 29.7 months, Q3: not reached and Q4: 17.0 months, 
p=0.064; figure 2A,B). The baseline levels of C4G, C3M, 
C4M or VICM were not significantly associated with PFS 
or OS (figures 1 and 2). Of note, PRO- C3 and PC3X levels 
were moderately correlated with each other at baseline 
(Pearson’s r=0.60, p<0.0001), while C3M and C4M were 
strongly correlated at baseline (Pearson’s r=0.86, p<0.0001; 
online supplemental table 1). Interestingly, patients with 
a high C3M/PRO- C3 ratio (>1) at baseline had improved 
PFS (median PFS: 15.5 vs 2.8 months, p=0.020) and OS 
(median OS: 42.3 vs 4.6 months, p<0.001) compared with 
patients with a low C3M/PRO- C3 ratio (<1) (figure 3A,B).
Excessive type III collagen turnover are independently related 
to worse outcome when assessed by Cox regression analysis
To evaluate association of the biomarkers with PFS and 
OS, univariate Cox regression analyses were performed 
of all ECM biomarkers and the common baseline patient 
risk factors: gender, age, WHO, brain metastasis and LDH.
When assessing PFS, then LDH, PRO- C3, PC3X, C4G 
and C3M levels as continuous test variables were associ-
ated with worse PFS (table 2).
Based on the Kaplan- Meier plot, the predictive value 
was also evaluated by using the 75th percentile cut- 
point (Q4) for the ECM biomarkers. Here, higher base-
line levels (Q4) of PRO- C3 (HR=1.96, 95% CI=1.17 to 
3.30, p=0.011), PC3X (HR=2.05, 95% CI=1.23 to 3.43, 
p=0.006), C4G (HR=1.93, 95% CI=1.15 to 3.26, p=0.014) 
and C3M (HR=1.75, 95% CI=1.04 to 2.93, p=0.036) were 
negatively related to PFS compared with lower levels 
(Q1–Q3) (table 2). Moreover, a high C3M/PRO- C3 ratio 
(>1) was associated with improved PFS (HR=0.51, 95% 
CI=0.29 to 0.91, p=0.023).
Table 1 Patient characteristics
Patient factor N (%)
Gender
  Male 62 (58%)
  Female 45 (42%)
WHO performance
  0 69 (64%)
  1 30 (28%)
  2 2 (2%)
  Unknown 6 (6%)
Treatment regimen
  Nivolumab 62 (58%)
  Pembrolizumab 45 (42%)
Prior systemic treatment lines
  0 88 (82%)
  1 18 (17%)
  2 1 (1%)
Brain metastases
  Present at baseline 18 (17%)
  Absent at baseline 48 (45%)
  No screening performed 41 (38%)
BOR
  CR 15 (14%)
  PR 38 (35.5%)
  SD 13 (12%)
  PD 38 (35.5%)
  Not evaluable 3 (3%)
Continuous variables Median (IQR)
  Age 66 (55–73)
  LDH at baseline 216 (183–306)
BOR, best overall response; CR, complete response; LDH, lactate 
dehydrogenase; PD, progressive disease; PD, partial response; SD, 
stable disease.
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In the multivariate analysis, PRO- C3 and PC3X levels 
were both independently related to worse PFS after 
correction for LDH (HR=1.81, 95% CI=1.06 to 3.10, 
p=0.030 and HR=1.86, 95% CI=1.09 to 3.18, p=0.023, 
respectively; table 2), although baseline PRO- C3 and 
PC3X were moderately correlated with baseline LDH 
(p<0.0001; online supplemental table 1).
When assessing OS in the univariate analysis, PRO- C3, 
PC3X and LDH as continuous variables and brain metas-
tases and WHO as categorical variables were negatively 
associated with OS (table 3). Similar to PFS, high PRO- C3 
(Q4) (HR=2.41, 95% CI=1.26 to 4.60, p=0.008) and PC3X 
(HR=2.21, 95% CI=1.14 to 4.28, p=0.019) were associ-
ated with worse OS compared with lower levels (Q1–Q3) 
(table 3). Again, a high C3M/PRO- C3 ratio (>1) was 
related to improved OS (HR=0.33, 95% CI=0.16 to 0.65, 
p=0.001) compared with a low ratio (table 3).
In the multivariate analysis, two models were tested. In 
the first model, each ECM biomarker was adjusted for 
the commonly used serum marker LDH. In the second 
model, the biomarkers were adjusted for both LDH, 
WHO and brain metastases as all three factors were 
predictive for OS. Two models were tested because infor-
mation about brain metastases is missing in about 40% 
of cases.
Importantly, PRO- C3 remained significantly associ-
ated with worse OS after adjustment for LDH (HR=2.08, 
95% CI=1.06 to 4.09, p=0.035), with a similar trend for 
PC3X that did not however meet statistical significance 
(HR=1.78, 95% CI=0.88 to 3.60, p=0.106; table 3). In 
line with previous findings, a high C3M/PRO- C3 ratio 
was related to improved OS when adjusted for LDH 
(HR=0.42, 95% CI=0.20 to 0.90, p=0.025; table 3). When 
all three factors (LDH, WHO and brain metastases) were 
included in the multivariate analysis, the predictive values 
were attenuated.
When assessing the effects of nivolumab versus 
pembrolizumab on PFS and OS in patients with low (Q1–
Q3) and high (Q4) biomarker levels, respectively, the 
only significant association was found for patients with 
low PC3X, who had improved PFS when treated with 
pembrolizumab compared with nivolumab (HR=0.51, 
Figure 1 Association of extracellular matrix (ECM) biomarkers measured at baseline and progression- free survival (PFS). 
Kaplan- Meier plots demonstrating the association of ECM biomarkers with PFS for patients with metastatic melanoma. (A) 
PRO- C3, (B) PC3X, (C) C4G, (D) C3M, (E) C4M and (F) VICM were dichotomized into quartiles (Q4, representing the highest 
levels of the biomarker). P values are based on the log- rank test. C3M, C4M, matrix metalloprotease (MMP)- degraded type III 
and IV collagen; C4G, granzyme B- degraded type IV collagen; PC3X, cross- linked N- terminal pro- peptide of type III collagen; 
PRO- C3, N- terminal pro- peptide of type III collagen; VICM, citrullinated and MMP- degraded vimentin.
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95% CI=0.27 to 0.96, p=0.038) (online supplemental 
table 2).
Baseline levels of PRO-C3 are associated with progressive 
disease
The relationship between baseline levels of the ECM 
biomarkers and the BOR was assessed. When comparing 
patients with PD with patients achieving disease control 
(BOR of SD, PR or CR), baseline PRO- C3 levels were 
significantly elevated in patients with PD (median 10.5 ng/
mL; 95% CI=8.3 to 12.7 vs 8.8 ng/mL; 95% CI=7.6 to 
9.9, p=0.046; online supplemental figure 2A). No signif-
icant differences were observed for the remaining five 
biomarkers (online supplemental figure 2B–F).
An increase of VICM levels during treatment was positively 
associated with clinical outcome
The dynamics of collagen and VICM turnover were 
assessed during PD-1 inhibition by comparing the base-
line biomarker levels with the levels after PD-1 ICI therapy. 
For PRO- C3, PC3X and VICM, an increase of serum levels 
Figure 2 Association of extracellular matrix (ECM) biomarkers measured at baseline and overall survival (OS). Kaplan- Meier 
plots demonstrating the association of ECM biomarkers with OS for patients with metastatic melanoma. (A) PRO- C3, (B) PC3X, 
(C) C4G, (D) C3M, (E) C4M and (F) VICM were dichotomized into quartiles (Q4, representing the highest levels of the biomarker). 
P values are based on the log- rank test. C3M, C4M, matrix metalloprotease (MMP)- degraded type III and IV collagen; C4G, 
granzyme B- degraded type IV collagen; PC3X, cross- linked N- terminal pro- peptide of type III collagen; PRO- C3, N- terminal 
pro- peptide of type III collagen; VICM, citrullinated and MMP- degraded vimentin.
Figure 3 A high C3M/PRO- C3 ratio at baseline associate 
with good survival outcomes. Kaplan- Meier plots 
demonstrating the association of the C3M/PRO- C3 ratio with 
progression- free survival (PFS) (A) and overall survival (OS) 
(B) for patients with metastatic melanoma. Patients were 
divided based on a C3M/PRO- C3 ratio >1 or <1 and a log- 
rank test was used to determine differences between survival 
curves. C3M,matrix metalloprotease (MMP)- degraded type 
III collagen; PRO- C3, N- terminal pro- peptide of type III 
collagen.
 on M
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was observed after 6 weeks of therapy compared with 
baseline (PRO- C3: 10.2 ng/mL; 95% CI=9.4 to 12.1 vs 
9.0 ng/mL; 95% CI=8.3 to 9.9; p<0.0001, PC3X: 5.7 ng/
mL; 95% CI=5.2 to 6.3 vs 4.9 ng/mL; 95% CI=4.4 to 5.6; 
p=0.003 and VICM: 21.4 ng/mL; 95% CI=17.0 to 25.7 
vs 15.0 ng/mL 95% CI=12.6 to 18.1; p<0.0001; online 
supplemental figure 3). Neither C4G, C3M or C4M 
changed significantly after treatment. Of note, the levels 
of all six biomarkers were highly correlated before and 
after 6 weeks of treatment (online supplemental table 3). 
Next, the association between biomarker levels during 
therapy and PFS and OS was assessed.
By the Kaplan- Meier approach, moderate significant 
differences of PFS were observed for quartile groups of 
PRO- C3 (p=0.011), C4G (p=0.017) and C4M (p=0.046) 
levels (online supplemental figure 4). The levels of the 
ECM biomarkers during therapy were not significantly 
associated with OS (online supplemental figure 5). Next, 
stratification was performed into patients who had an 
evident increase of the ECM biomarker during therapy 
(of >20% from baseline) and patients who did not have 
an evident increase (the remaining patients). Patients 
with an increase of VICM during therapy seemed to have, 
although not significant, an improved PFS assessed by the 
Kaplan- Meier approach (median PFS: 28.4 vs 8.4 months, 
p=0.053) (figure 4C) and by univariate Cox regression 
(HR=0.59, 95% CI=0.35 to 1.01, p=0.056). The OS in 
these patients was significantly improved (Kaplan- Meier 
(figure 4F): median OS: 42.3 vs 36.2 months, p=0.015 and 
univariate Cox regression: HR=0.39, 95% CI=0.19 to 0.86, 
p=0.018). VICM remained significant after correction 
for WHO performance status, brain metastases and LDH 
(HR=0.28, 95% CI=0.10 to 0.77, p=0.014) and LDH alone 
(HR=0.42, 95% CI=0.20 to 0.91, p=0.028). No significant 
Table 2 Univariate and multivariate Cox regression analysis of the association of patient factors and ECM biomarkers with 










P valueHR (95% CI) HR (95% CI)
Gender Male vs female 40/62 vs 26/44 1.14 (0.69 to 1.86) 0.611
Age Continuous (year) 66/106 1.00 (0.99 to 1.02) 0.744
WHO >1 vs 0 27/37 vs 39/69 1.60 (0.98 to 2.62) 0.061
Brain 
metastasis
Present vs absent 12/18 vs 33/47 1.00 (0.52 to 1.94) 0.997
LDH Continuous (U/L) 66/106 1.00 (1.00 to 1.00) 0.014*
PRO- C3 Continuous (ng/mL) 66/106 1.02 (1.00 to 1.04) 0.031*
4.0–12.5 ng/mL, Q1-–Q3 45/79 1.00 – 45/79
12.6–84.7 ng/mL, Q4 21/27 1.96 (1.17 to 3.30) 0.011* 21/27 1.81 (1.06 to 3.10) 0.030*
PC3X Continuous (ng/mL) 66/10644/79 1.04 (1.00 to 1.07) 0.046*
1.2–7.6 ng/mL, Q1-–Q3 1.00 – 44/79
7.6–30.2 ng/mL, Q4 22/27 2.05 (1.23 to 3.43) 0.006** 22/27 1.86 (1.09 to 3.18) 0.023*
C4G Continuous (ng/mL) 65/105 1.01 (1.00 to 1.02) 0.019*
7.8–27.3 ng/mL, Q1-–Q3 44/79 1.00 – 44/79
27.4–125.7 ng/mL, Q4 21/26 1.93 (1.15 to 3.26) 0.014* 21/26 1.91 (1.13 to 3.23) 0.016*
C3M Continuous (ng/mL) 66/106 1.04 (1.00 to 1.09) 0.038*
8.2–19.5 ng/mL, Q1–Q3 45/79 1.00 – 45/79
19.6–36.0 ng/mL, Q4 21/27 1.75 (1.04 to 2.93) 0.036* 21/27 1.67 (0.99 to 2.82) 0.054
C4M Continuous (ng/mL) 66/106 1.01 (1.00 to 1.03) 0.158
8.8–38.0 ng/mL, Q1–Q3 47/79 1.00 – 47/79
38.8–87.1 ng/mL, Q4 19/27 1.29 (0.76 to 2.20) 0.349 19/27 1.19 (0.69 to 2.04) 0.532
VICM Continuous (ng/mL) 66/106 1.01 (1.00 to 1.02) 0.121
1.0–23.4 ng/mL, Q1–Q3 48/79 1.00 – 48/79
23.7–132.3 ng/mL, Q4 18/27 1.16 (0.67 to 1.99) 0.602 18/27 1.27 (0.73 to 2.20) 0.401
C3M/
PRO- C3
>1 vs <1 51/88 vs 15/18 0.51 (0.29 to 0.91) 0.023* 51/88 vs 
15/18
0.59 (0.32 to 1.11) 0.102
HR were calculated by univariate and multivariate cox regression analysis. By the multivariate analysis, the individual biomarkers were adjusted for 
LDH. Significance is marked with stars.
C4G, granzyme B- degraded type IV collagen; C3M, C4M, matrix metalloprotease (MMP)- degraded type III and IV collagen; ECM, extracellular matrix; 
LDH, lactate dehydrogenase; PC3X, cross- linked N- terminal pro- peptide of type III collagen; PRO- C3, N- terminal pro- peptide of type III collagen; 
VICM, citrullinated and MMP- degraded vimentin; WHO, WHO performance score.
 on M
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differences were observed for PRO- C3 or PC3X, although 
a trend could be observed for increased PRO- C3 and 
PC3X levels and worse OS (figure 4A–E).
DISCUSSION
The present study demonstrates that blood- based 
biomarkers of protease- generated neo- epitopes on protein 
fragments reflecting altered ECM turnover are associated 
with clinical outcome after PD-1 ICI therapy in metastatic 
melanoma. Baseline serum levels of ECM protein frag-
ments PRO- C3 and PC3X, indicating a collagen- rich peri-
tumoral stroma and fibrotic activity, were associated with 
resistance to PD-1 inhibition. Moreover, upregulation of 
VICM during therapy, reflecting M1 macrophage activity, 
was associated with improved survival.
Patients with higher PRO- C3 and PC3X levels had 
worse clinical outcome after PD-1 inhibition compared 
with patients with lower levels. Interestingly, as PRO- C3 
and PC3X are released to the blood circulation during 
excessive collagen formation and cross- linking,16 the find-
ings suggest that those markers identify tumors with an 
immune- excluded phenotype. Immune- exclusion is char-
acterized by dense collagen stroma that limits the entry 
of tumor infiltrating lymphocytes into the TME, which 
is considered as an important biological mechanism of 
therapy resistance.4 17 Cytotoxic T cell activity towards 
cancer cells in the TME is suggested to be an independent 
factor of the PD- L1 tumor proportion score and tumor 
mutation burden.2 18
Although these protease- generated protein fragments 
were significantly correlated to LDH levels, we demon-
strated that higher PRO- C3, independent of LDH, was 
associated with worse PFS and OS and that higher PC3X 
was associated with worse PFS. LDH is known as a marker 
of tumor burden and a clinically significant adverse 
prognostic factor for metastatic melanoma, which is also 
confirmed in this immuno- oncology setting.19 Elevated 
LDH levels is integrated as a suffix to the M1 subcatego-
ries in recent TNM cancer staging protocols,20 providing 
additional prognostic value. Interestingly, similar obser-
vations for PRO- C3 were previously seen in patients with 
metastatic melanoma who were treated with CTLA-4 ICI 
therapy,13 suggesting that the non- invasive biomarker may 
be considered across different ICIs.
Dense collagen stroma may also affect the diffusion 
and distribution of the therapeutic antibodies,21 in addi-
tion to its effect in limiting the entry of tumor infiltrating 
lymphocytes into the TME. Previous work by Jensen et al13 
demonstrated additional prognostic value of the ratio of 
type III collagen degradation to formation (C3M/PRO- 
C3) after CTLA-4 inhibition in metastatic melanoma. The 
present findings confirm that patients with a high C3M/
PRO- C3 ratio (>1) are linked to better clinical outcome 
after PD-1 inhibition, thereby providing additional 
Figure 4 Increase in VICM after anti- programmed cell death protein 1 (anti- PD-1) treatment associates with progression- free 
survival (PFS) and overall survival (OS). Kaplan- Meier plots demonstrating the association of change in PRO- C3 (A, D), PC3X (B, 
E) and VICM (C, F) with PFS and OS 6 weeks after start of anti- PD-1 immune checkpoint inhibitor (ICI) therapy after stratification 
of patients based on an increase of >20% from baseline vs <20% increase. P values are based on the log- rank test. PC3X, 
cross- linked N- terminal pro- peptide of type III collagen; PRO- C3, N- terminal pro- peptide of type III collagen; VICM, citrullinated 
and MMP- degraded vimentin.
 on M
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evidence for the hypothesis that patients with relatively 
low net fibrosis/collagen deposition are more likely to 
respond to ICIs. PRO- C3 and PC3X are associated with a 
higher activity of CAFs. In addition to the desmoplastic, 
collagen- rich TME related to immune- exclusion, CAFs 
have also shown to contribute to a diminished immune 
function by expressing TGF-β, PD- L1/PD- L2 and by 
inducing immune checkpoints on T cells.6 22–24
We demonstrated that patients with an increase in 
VICM during treatment had improved clinical outcome. 
VICM is released from activated inflammatory M1 
macrophages,25 which may be an important factor for 
response to ICIs compared with the immune- suppressive 
M2 macrophage phenotype. For example, PD- L1 inhi-
bition was demonstrated to polarize macrophages into 
a more pro- inflammatory phenotype, which was associ-
ated with enhanced T cell activity.26 In mice, PD-1 inhi-
bition was found to increase macrophage phagocytosis, 
and was associated with better survival in a macrophage- 
dependent fashion.27 Our results support these findings 
and additionally suggest that blood- based VICM levels 
have potential value for monitoring early response to 
PD-1 inhibition.
Whereas higher C4M levels at baseline were previously 
demonstrated to be associated with worse clinical outcome 
after CTLA-4 inhibition in metastatic melanoma,13 we 
could not confirm this observation after PD-1 inhibition. 
C4M mirrors basement membrane remodeling, which is 
strongly associated with malignant progression of cancer.28 
These inconsistent results may be explained either by the 
difference of mechanism of action of CTLA-4 and PD-1 
inhibition or by the higher efficacy of PD-1 inhibition in 
this immuno- oncology setting.13
Interestingly, C4G levels were previously associated with 
improved OS after CTLA-4 inhibition in metastatic mela-
noma.29 This C4G biomarker measures a neo- epitope of 
C4G that may reflect cytotoxic T- cell infiltration in the 
TME.30 Nevertheless, we could not observe a relation-
ship between C4G levels and clinical outcome after PD-1. 
Granzyme B is a key serine protease that is secreted by 
activated T and NK cells to induce apoptosis.31 While it 
is suggested to contribute to response mechanisms of 
PD-1 inhibition in metastatic lung cancer, illustrated by 
an inverse relationship of both granzyme B levels as well 
as germline variation of GZMB and clinical outcome,32 
further research is needed to elaborate on the differences 
between ICIs and tumor types.33
Despite the interesting findings, this study also has 
some limitations. Patients were treated with two different 
ICIs (nivolumab or pembrolizumab) and not designed/
powered to differentiate between the two. Although 
these are highly similar monoclonal antibodies directed 
to the PD-1 receptor, this may have an impact on the 
results. Furthermore, the sample size was too small to 
correct for multiple testing or for splitting the patients 
into a discovery and validation group. Nevertheless, in 
the current analysis we were able to demonstrate strong 
associations with survival outcomes for a selection of ECM 
biomarkers. Although ECM turnover is a physiological 
process taking place throughout the body, the assess-
ments of specific post- translational modifications (neo- 
epitopes) may reduce the systemic background of healthy 
turnover and instead increase the specificity of ECM 
turnover in the TME.12 34 Besides, even though our main 
objective was to investigate the association of markers with 
clinical outcome, the findings do not address the predic-
tive performance of the biomarkers, for which prospec-
tive external validation is needed in cohorts randomized 
to different modalities. Lastly, a statistical methodology is 
needed to determine the cut- off discriminating high and 
low levels of these molecules. This is of particular impor-
tance for validation in a randomized setting for estab-
lishing the performance of biomarkers for diagnostic 
use, which was not the scope of this study. Here, cutoffs 
may be selected by receiver operating characteristics. We 
believe that identification of patients who have primary 
resistance should require a high negative predictive value, 
consequently with stringent cut- off values.
CONCLUSIONS
In conclusion, we demonstrated that the ECM protein 
fragments PRO- C3 and PC3X in baseline serum, repre-
senting a dense collagen stroma, were associated with 
worse clinical outcome after PD-1 inhibition in meta-
static melanoma. Moreover, increasing VICM levels early 
during therapy was associated with improved survival. 
VICM levels correspond with M1 macrophage activity by 
its specific release of MMP- degraded and citrullinated 
vimentin in the blood circulation. After validation, these 
biomarkers may provide a robust non- invasive tool for 
patient stratification and therapeutic decision- making in 
immuno- oncology.
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